Business Information
The group's principal activities are carried out through three main business divisions: genzyme general, genzyme molecular oncology and genzyme biosurgery. Genzyme general develops and markets therapeutic proteins, surgical and diagnostic products, genetic diagnostic services, and pharmaceuticals. Genzyme biosurgery is organized into three business units: orthopaedics, cardiothoracic and biosurgical specialties. Biosurgery develops and markets instruments, devices, biomaterials and biotherapeutic products to improve or replace surgery, with an emphasis on the orthopaedics and cardiothoracic markets. Genzyme molecular oncology develops gene-based approaches to cancer therapy through genomics and gene therapy therapeutics accounted for 53% of 2002 revenues; genzyme biosurgery, 18%; renal, 12%; diagnostic products, 6%; genzyme molecular oncology, 1% and other, 10%.
|
|
Name |
Title
|
Email
|
| Henri Termeer | Chmn., CEO, Pres. | N/A | | Ann Merrifield | Pres. - Genzyme Biosurgery | N/A | | David Meeker | Pres. - Lysosomal Storage Disorder Therapeutics | N/A | | Donald Pogorzelski | Pres. - Genzyme Diagnostics | N/A | | John Butler | Pres. - Genzyme Renal | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 3,187,013 | (16,797) | | 2005 | 2,734,842 | 441,489 | | 2004 | 2,201,145 | 86,527
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
